from ANP's anns today
The targeting of B cells has recently become a particularly high area of interest in
MS treatment. Accordingly, the Company is refocussing its clinical development strategy to include SPMS
and is currently finalising the design of a Phase IIb trial in SP-MS patients (see below IND
submission).
IMU is not targeting MS but the more the focus shifts towards the B-cell technology in general the more valuable will IMU's IP become. Like lithium, not long to wait before any stock that mentions " B-Cell " will be send sky high by the traders.
Only fools are selling IMU.
The B-cell mania is getting closer
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |